BridgeBio Pharma to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-Type Transthyretin Amyloid Cardiomyopathy at the ACC Annual Scientific Sessions

BridgeBio Pharma
Today, March 24, 2025, BridgeBio Pharma, Inc. (BBIO) announced that cardiovascular outcomes data in patients with variant and wild-type ATTR-CM from the ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a flatboard poster presentation at the American College . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.